Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

METTL13 Methylation of eEF1A Increases Translational Output to Promote Tumorigenesis.

Liu S, Hausmann S, Carlson SM, Fuentes ME, Francis JW, Pillai R, Lofgren SM, Hulea L, Tandoc K, Lu J, Li A, Nguyen ND, Caporicci M, Kim MP, Maitra A, Wang H, Wistuba II, Porco JA Jr, Bassik MC, Elias JE, Song J, Topisirovic I, Van Rechem C, Mazur PK, Gozani O.

Cell. 2019 Jan 24;176(3):491-504.e21. doi: 10.1016/j.cell.2018.11.038. Epub 2019 Jan 3.

PMID:
30612740
2.

Neat1 is a p53-inducible lincRNA essential for transformation suppression.

Mello SS, Sinow C, Raj N, Mazur PK, Bieging-Rolett K, Broz DK, Imam JFC, Vogel H, Wood LD, Sage J, Hirose T, Nakagawa S, Rinn J, Attardi LD.

Genes Dev. 2017 Jun 1;31(11):1095-1108. doi: 10.1101/gad.284661.116. Epub 2017 Jul 11.

3.

An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer.

Vallejo A, Perurena N, Guruceaga E, Mazur PK, Martinez-Canarias S, Zandueta C, Valencia K, Arricibita A, Gwinn D, Sayles LC, Chuang CH, Guembe L, Bailey P, Chang DK, Biankin A, Ponz-Sarvise M, Andersen JB, Khatri P, Bozec A, Sweet-Cordero EA, Sage J, Lecanda F, Vicent S.

Nat Commun. 2017 Feb 21;8:14294. doi: 10.1038/ncomms14294.

4.

Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer.

Jahchan NS, Lim JS, Bola B, Morris K, Seitz G, Tran KQ, Xu L, Trapani F, Morrow CJ, Cristea S, Coles GL, Yang D, Vaka D, Kareta MS, George J, Mazur PK, Nguyen T, Anderson WC, Dylla SJ, Blackhall F, Peifer M, Dive C, Sage J.

Cell Rep. 2016 Jul 19;16(3):644-56. doi: 10.1016/j.celrep.2016.06.021. Epub 2016 Jun 30.

5.

Novel insights into the oncogenic function of the SMYD3 lysine methyltransferase.

Mazur PK, Gozani O, Sage J, Reynoird N.

Transl Cancer Res. 2016 Jun;5(3):330-333. doi: 10.21037/tcr.2016.06.26. No abstract available.

6.

Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors.

Krampitz GW, George BM, Willingham SB, Volkmer JP, Weiskopf K, Jahchan N, Newman AM, Sahoo D, Zemek AJ, Yanovsky RL, Nguyen JK, Schnorr PJ, Mazur PK, Sage J, Longacre TA, Visser BC, Poultsides GA, Norton JA, Weissman IL.

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4464-9. doi: 10.1073/pnas.1600007113. Epub 2016 Mar 31. Erratum in: Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):E5538.

7.

Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer.

Reynoird N, Mazur PK, Stellfeld T, Flores NM, Lofgren SM, Carlson SM, Brambilla E, Hainaut P, Kaznowska EB, Arrowsmith CH, Khatri P, Stresemann C, Gozani O, Sage J.

Genes Dev. 2016 Apr 1;30(7):772-85. doi: 10.1101/gad.275529.115. Epub 2016 Mar 17.

8.

Pancreatic cancer takes its Toll.

Mazur PK, Sage J.

J Exp Med. 2015 Nov 16;212(12):1988. doi: 10.1084/jem.21212insight1. No abstract available.

9.

Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.

Mazur PK, Herner A, Mello SS, Wirth M, Hausmann S, Sánchez-Rivera FJ, Lofgren SM, Kuschma T, Hahn SA, Vangala D, Trajkovic-Arsic M, Gupta A, Heid I, Noël PB, Braren R, Erkan M, Kleeff J, Sipos B, Sayles LC, Heikenwalder M, Heßmann E, Ellenrieder V, Esposito I, Jacks T, Bradner JE, Khatri P, Sweet-Cordero EA, Attardi LD, Schmid RM, Schneider G, Sage J, Siveke JT.

Nat Med. 2015 Oct;21(10):1163-71. doi: 10.1038/nm.3952. Epub 2015 Sep 21.

10.

Current methods in mouse models of pancreatic cancer.

Mazur PK, Herner A, Neff F, Siveke JT.

Methods Mol Biol. 2015;1267:185-215. doi: 10.1007/978-1-4939-2297-0_9.

PMID:
25636470
11.

SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.

Mazur PK, Reynoird N, Khatri P, Jansen PW, Wilkinson AW, Liu S, Barbash O, Van Aller GS, Huddleston M, Dhanak D, Tummino PJ, Kruger RG, Garcia BA, Butte AJ, Vermeulen M, Sage J, Gozani O.

Nature. 2014 Jun 12;510(7504):283-7. doi: 10.1038/nature13320. Epub 2014 May 21.

12.

A meta-analysis of lung cancer gene expression identifies PTK7 as a survival gene in lung adenocarcinoma.

Chen R, Khatri P, Mazur PK, Polin M, Zheng Y, Vaka D, Hoang CD, Shrager J, Xu Y, Vicent S, Butte AJ, Sweet-Cordero EA.

Cancer Res. 2014 May 15;74(10):2892-902. doi: 10.1158/0008-5472.CAN-13-2775. Epub 2014 Mar 20.

13.

Current methods in the molecular typing of Mycobacterium tuberculosis and other mycobacteria.

Jagielski T, van Ingen J, Rastogi N, Dziadek J, Mazur PK, Bielecki J.

Biomed Res Int. 2014;2014:645802. doi: 10.1155/2014/645802. Epub 2014 Jan 5. Review.

14.

Opposing role of Notch1 and Notch2 in a Kras(G12D)-driven murine non-small cell lung cancer model.

Baumgart A, Mazur PK, Anton M, Rudelius M, Schwamborn K, Feuchtinger A, Behnke K, Walch A, Braren R, Peschel C, Duyster J, Siveke JT, Dechow T.

Oncogene. 2015 Jan 29;34(5):578-88. doi: 10.1038/onc.2013.592. Epub 2014 Feb 10.

PMID:
24509876
15.

A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors.

Jahchan NS, Dudley JT, Mazur PK, Flores N, Yang D, Palmerton A, Zmoos AF, Vaka D, Tran KQ, Zhou M, Krasinska K, Riess JW, Neal JW, Khatri P, Park KS, Butte AJ, Sage J.

Cancer Discov. 2013 Dec;3(12):1364-77. doi: 10.1158/2159-8290.CD-13-0183. Epub 2013 Sep 26.

16.

IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors.

Jameson KL, Mazur PK, Zehnder AM, Zhang J, Zarnegar B, Sage J, Khavari PA.

Nat Med. 2013 May;19(5):626-630. doi: 10.1038/nm.3165. Epub 2013 Apr 21.

17.

EGF receptor is required for KRAS-induced pancreatic tumorigenesis.

Ardito CM, Grüner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur PK, Delgiorno KE, Carpenter ES, Halbrook CJ, Hall JC, Pal D, Briel T, Herner A, Trajkovic-Arsic M, Sipos B, Liou GY, Storz P, Murray NR, Threadgill DW, Sibilia M, Washington MK, Wilson CL, Schmid RM, Raines EW, Crawford HC, Siveke JT.

Cancer Cell. 2012 Sep 11;22(3):304-17. doi: 10.1016/j.ccr.2012.07.024.

18.

MALDI imaging mass spectrometry for in situ proteomic analysis of preneoplastic lesions in pancreatic cancer.

Grüner BM, Hahne H, Mazur PK, Trajkovic-Arsic M, Maier S, Esposito I, Kalideris E, Michalski CW, Kleeff J, Rauser S, Schmid RM, Küster B, Walch A, Siveke JT.

PLoS One. 2012;7(6):e39424. doi: 10.1371/journal.pone.0039424. Epub 2012 Jun 26.

19.

Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues.

Aichler M, Seiler C, Tost M, Siveke J, Mazur PK, Da Silva-Buttkus P, Bartsch DK, Langer P, Chiblak S, Dürr A, Höfler H, Klöppel G, Müller-Decker K, Brielmeier M, Esposito I.

J Pathol. 2012 Apr;226(5):723-34. doi: 10.1002/path.3017. Epub 2012 Jan 17.

PMID:
21984419
20.

Expression and clinicopathological significance of notch signaling and cell-fate genes in biliary tract cancer.

Mazur PK, Riener MO, Jochum W, Kristiansen G, Weber A, Schmid RM, Siveke JT.

Am J Gastroenterol. 2012 Jan;107(1):126-35. doi: 10.1038/ajg.2011.305. Epub 2011 Sep 20.

PMID:
21931375
21.

Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway.

Viatour P, Ehmer U, Saddic LA, Dorrell C, Andersen JB, Lin C, Zmoos AF, Mazur PK, Schaffer BE, Ostermeier A, Vogel H, Sylvester KG, Thorgeirsson SS, Grompe M, Sage J.

J Exp Med. 2011 Sep 26;208(10):1963-76. doi: 10.1084/jem.20110198. Epub 2011 Aug 29.

22.

Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology.

Mazur PK, Siveke JT.

Gut. 2012 Oct;61(10):1488-500. doi: 10.1136/gutjnl-2011-300756. Epub 2011 Aug 26. Review.

PMID:
21873467
23.

Early requirement of Rac1 in a mouse model of pancreatic cancer.

Heid I, Lubeseder-Martellato C, Sipos B, Mazur PK, Lesina M, Schmid RM, Siveke JT.

Gastroenterology. 2011 Aug;141(2):719-30, 730.e1-7. doi: 10.1053/j.gastro.2011.04.043. Epub 2011 Apr 28.

PMID:
21684285
24.

Identification of epidermal Pdx1 expression discloses different roles of Notch1 and Notch2 in murine Kras(G12D)-induced skin carcinogenesis in vivo.

Mazur PK, Grüner BM, Nakhai H, Sipos B, Zimber-Strobl U, Strobl LJ, Radtke F, Schmid RM, Siveke JT.

PLoS One. 2010 Oct 22;5(10):e13578. doi: 10.1371/journal.pone.0013578.

25.

Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma.

Mazur PK, Einwächter H, Lee M, Sipos B, Nakhai H, Rad R, Zimber-Strobl U, Strobl LJ, Radtke F, Klöppel G, Schmid RM, Siveke JT.

Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13438-43. doi: 10.1073/pnas.1002423107. Epub 2010 Jul 12.

26.

Liver-specific inactivation of Notch2, but not Notch1, compromises intrahepatic bile duct development in mice.

Geisler F, Nagl F, Mazur PK, Lee M, Zimber-Strobl U, Strobl LJ, Radtke F, Schmid RM, Siveke JT.

Hepatology. 2008 Aug;48(2):607-16. doi: 10.1002/hep.22381.

PMID:
18666240
27.

Conditional ablation of Notch signaling in pancreatic development.

Nakhai H, Siveke JT, Klein B, Mendoza-Torres L, Mazur PK, Algül H, Radtke F, Strobl L, Zimber-Strobl U, Schmid RM.

Development. 2008 Aug;135(16):2757-65. doi: 10.1242/dev.013722. Epub 2008 Jul 17.

28.

Notch signaling is required for exocrine regeneration after acute pancreatitis.

Siveke JT, Lubeseder-Martellato C, Lee M, Mazur PK, Nakhai H, Radtke F, Schmid RM.

Gastroenterology. 2008 Feb;134(2):544-55. doi: 10.1053/j.gastro.2007.11.003. Epub 2007 Nov 4.

PMID:
18242220

Supplemental Content

Loading ...
Support Center